Molecular Diagnosis of the Tissue of Origin in Cancer of Unknown Primary Site: Useful in Patient Management

2013 ◽  
Vol 14 (4) ◽  
pp. 634-642 ◽  
Author(s):  
F. Anthony Greco
Keyword(s):  
Molecular Diagnosis ◽  
Patient Management ◽  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Unknown Primary ◽  
Unknown Primary Site ◽  
Tissue Of Origin

Prospective gene signature study using microRNA to predict the tissue of origin (ToO) in pts with cancer of unknown primary site (CUP).

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 4151-4151 ◽  
Author(s):  
G. R. Varadhachary ◽  
T. B. Edmonston ◽  
S. Karanth ◽  
H. R. Carlson ◽  
D. Lebanony ◽  
...  
Keyword(s):  
Gene Signature ◽  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Unknown Primary ◽  
Unknown Primary Site ◽  
Tissue Of Origin

Economic analysis of epicup, an epigenetic test to predict the tissue of origin in cancer of unknown primary site.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e12532-e12532
Author(s):  
Carmen Balana ◽  
Alfredo Gracia ◽  
Lisette Kaskens ◽  
Sebastian Chiavenna ◽  
Xavier Matias-Guiu ◽  
...  
Keyword(s):  
Economic Analysis ◽  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Unknown Primary ◽  
Unknown Primary Site ◽  
Tissue Of Origin

Cancer of Unknown Primary Site: Improved Patient Management with Molecular and Immunohistochemical Diagnosis

2013 ◽  
pp. 175-181 ◽  
Author(s):  
F. Anthony Greco
Keyword(s):  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Diagnostic Tools ◽  
Unknown Primary ◽  
Unknown Primary Site ◽  
Large Prospective Study ◽  
Tissue Of Origin ◽  
Immunohistochemical Diagnosis ◽  
Molecular Aberrations ◽  
Tumor Types

Cancer of unknown primary site (CUP) is a common heterogeneous clinicopathologic syndrome, but investigations and publications regarding these patients are rare. For the last 20 years, empiric “broad-spectrum” chemotherapy has been the standard therapy for the majority of these patients. More recently, improved immunocytochemistry and advent of gene-expression profiling have provided the diagnostic tools necessary to accurately define the tissue of origin in most patients. Molecular profiling assays complement standard pathologic diagnosis, and a recently reported large prospective study demonstrated an improvement in outcome for patients treated with site-specific therapy directed by the molecular assay diagnoses compared with empiric chemotherapy. Survival in molecularly diagnosed patients was as expected for those particular tumor types. The evaluation of patients has become more standardized. The empiric-chemotherapy era is ending and customized therapies based on accurate tissue of origin diagnoses have arrived. Eventually the recognition of the molecular aberrations responsible for the growth and metastasis of solid tumors, regardless of the tissue of origin, will lead to more precise and effective therapy for patients with advanced cancers.

scholarly journals Dermatomyositis Associated with Cancer of Unknown Primary Site

2007 ◽  
Vol 22 (Suppl) ◽  
pp. S174 ◽  
Author(s):  
Hyung Il Kim ◽  
Sung Hoon Chung ◽  
Jun Eul Hwang ◽  
Sang Ho Kim ◽  
Jae Sook Ahn ◽  
...  
Keyword(s):  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Unknown Primary ◽  
Unknown Primary Site

scholarly journals Cancer of Unknown Primary Site Mimicking Retroperitoneal Fibrosis

2018 ◽  
Vol 93 (6) ◽  
pp. 575-581
Author(s):  
Chan Keol Park ◽  
Su-Jin Yoo ◽  
In Seol Yoo ◽  
Jinhyun Kim ◽  
Seung Cheol Shim ◽  
...  
Keyword(s):  
Retroperitoneal Fibrosis ◽  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Unknown Primary ◽  
Unknown Primary Site
Sign in / Sign up

Export Citation Format

Share Document